X-ray Powder Diffraction and Crystal Structure Prediction for Polymorph Screening and Structure Solution in Pharmaceutical Development

Different polymorphs of the same active pharmaceutical ingredient can have significantly different physical and chemical properties, including solubility, hygroscopicity, compressibility, thermal stability, and mechanical behavior. These differences can affect bioavailability, formulation design, manufacturing performance, stability, regulatory strategy, and intellectual property.

Screening objectives can also change throughout development. Early work may focus on finding the most thermodynamically stable form, while later studies may seek a form with properties better suited to drug delivery or identify additional forms that could emerge during manufacturing and storage. Comprehensive polymorph screening therefore helps reduce technical and commercial risk throughout a drug's development.

CSP generates candidate crystal structures that can be stored as crystallographic information files and used to calculate theoretical PXRD patterns. These simulated patterns can then be compared directly with experimental PXRD data from solid forms produced during polymorph screening.

The experimental powder pattern can also be indexed to determine parameters such as the unit cell and Bravais lattice. Candidate structures can therefore be evaluated using both diffraction-pattern similarity and agreement between predicted and experimentally derived crystallographic parameters. This combination provides more robust candidate identification than relying on powder-pattern matching alone.

Yes. CSP-generated structures can provide starting models that are refined directly against experimental powder diffraction data. This is particularly useful for pharmaceutical compounds because solid-form screening often produces small quantities of powder rather than large, well-formed crystals suitable for single-crystal X-ray diffraction.

After likely CSP candidates are identified through powder-pattern and unit-cell comparisons, the closest candidate can be refined using whole-pattern fitting. Parameters such as lattice dimensions, peak profiles, scale factors, and molecular structural variables can be adjusted to obtain a structure consistent with the experimental PXRD data.

PXRD data from cimetidine powder were indexed to determine the experimental unit cell, space group, and related crystallographic information. A targeted CSP search then generated possible crystal structures using both fixed-lattice and global search strategies. Candidate structures underwent geometry optimization and energy ranking, followed by quantitative comparison of their simulated PXRD patterns with the experimental pattern.

Five promising candidates were selected for further evaluation. Comparison with the experimentally indexed Bravais lattice identified the strongest candidate, which was subsequently refined against the complete powder diffraction pattern. The refinement achieved an Rwp of 4.59%, and the resulting powder-derived molecular structure showed excellent agreement with the published single-crystal structure of cimetidine.

Comparing simulated and experimental diffraction patterns alone can be complicated by differences between predicted and measured lattice parameters. CSP structures often represent static or low-temperature lattices, whereas experimental PXRD measurements are commonly performed under ambient conditions. These differences can shift diffraction peak positions even when the underlying structures are closely related.

Indexing the measured pattern provides experimental unit-cell and Bravais-lattice information. Comparing those parameters with CSP-derived cells adds an independent crystallographic criterion for identifying the correct structure and can accommodate differences in crystallographic axis settings through appropriate cell transformations.

CSP can generate a database of predicted structures and corresponding CIF files before or alongside experimental screening. As PXRD patterns are collected from solid-form screening samples, the measured patterns can be compared automatically with calculated patterns from the CSP database. Candidate structures can then be ranked and the most promising matches passed to further analysis and refinement.

This approach turns CSP from a primarily predictive exercise into a practical screening tool. Integrating automated PXRD measurement, pattern analysis, candidate matching, and structural refinement can make it feasible to evaluate large numbers of pharmaceutical samples quickly and consistently while also providing structural information about newly observed forms.